Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving Broad-spectrum antibacterial therapy: A randomized, controlled trial

M. Boogaerts; D.J. Winston; E.J. Bow; G. Garber; A.C. Reboli; A.P. Schwarer; N. Novitzky; A. Boehme; E. Chwetzoff; K. de Beule; E. Phillips

doi:10.7326/0003-4819-135-6-200109180-00010

Back

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving Broad-spectrum antibacterial therapy: A randomized, controlled trial

Journal article

Peer reviewed

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving Broad-spectrum antibacterial therapy: A randomized, controlled trial

M. Boogaerts, D.J. Winston, E.J. Bow, G. Garber, A.C. Reboli, A.P. Schwarer, N. Novitzky, A. Boehme, E. Chwetzoff, K. de Beule, …

Annals of Internal Medicine, Vol.135(6), pp.412-422

2001

DOI: https://doi.org/10.7326/0003-4819-135-6-200109180-00010

Files and links (1)

url

Link to Published Version *Subscription may be requiredView

Abstract

Prolonged neutropenia is a major risk factor for invasive fungal infection (1–6). The incidence among neutropenic patients with cancer who are receiving intensive cytotoxic therapy ranges from 2% to 47%, depending on other concomitant risk factors (7). Mortality rates range from 35% to 90% (8). Fever may be the only clinical sign of infection, and definitive diagnosis is often problematic. Empirical therapy with amphotericin B deoxycholate reduces the relative risk for documented infection by 50% to 80% and overall mortality rates by 23% to 45% (1–2, 9–10). This practice is now standard in neutropenic patients with cancer who have persistent fever that does not respond to 3 to 7 days of treatment with broad-spectrum antibiotics (11).

Details

Title: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving Broad-spectrum antibacterial therapy: A randomized, controlled trial
Authors/Creators: M. Boogaerts (Author/Creator) - KU Leuven
D.J. Winston (Author/Creator)
E.J. Bow (Author/Creator)
G. Garber (Author/Creator)
A.C. Reboli (Author/Creator) - CMSRU
A.P. Schwarer (Author/Creator)
N. Novitzky (Author/Creator)
A. Boehme (Author/Creator)
E. Chwetzoff (Author/Creator)
K. de Beule (Author/Creator)
E. Phillips (Author/Creator)
Publication Details: Annals of Internal Medicine, Vol.135(6), pp.412-422
Publisher: American College of Physicians
Identifiers: 991005542607807891
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article
Note: Elizabeth Phillips appears on behalf of the Itraconazole Neutropenia Study Group

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

43 Record Views

243 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.148 Medical Mycology; 1.148.94 Antifungal Strategies
Web Of Science research areas: Microbiology
ESI research areas: Clinical Medicine